Patients who each year reach the end of that road. They exhaust standard treatment options, but they are not out of FDA-approved treatments. They are out of NCCN-approved options. 90% of FDA-approved cancer drugs remain untested for them.
Every cancer patient is a candidate for a better approach.
Every cancer patient is given the drugs that worked best for the average patient in a clinical trial, because until now there has been no way to find out what works for each patient.
THE BETTER APPROACH
“If you want to know whether a drug will work, why not expose a person's living cancer cells directly to the therapy and observe what happens? ”
This method is particularly beneficial for advanced cancer patients who have exhausted standard treatments. Functional tests can still identify effective therapies among over 300 FDA-approved cancer drugs.
Biopsy
Take the patient's live cancer cells.
Expose
Put approved cancer drugs on the individual's cells.
Measure
Observe which cancer drugs kill the cells.
Rank
Prioritize cancer drugs by what worked.
Treat
The oncologist composes a treatment or combination of treatments.
Repeat
When the cancer changes, run the test again.
Functional Precision Medicine works at any point in treatment, from the last line to the first. Every time a cancer changes, a new test can identify the next cancer drugs.
NCPO MAKES IT ACCESSIBLE
NCPO is a personalized oncology national resource to US hospitals, supporting 15,000 medical oncologists and over 2 million cancer patients annually.
FOR PATIENTS
A new-treatments resource
Access to approved cancer drugs tailored to each patient's cancer, without travel or trial requirements. Outcomes are tracked to enhance evidence with each patient.
Candidate treatment
Off-Guideline
Case N26709
Ordering Oncologist
Dr. A. Chen
Functional test score
92/100
FDA approval
Insurance documentation
Drafted
Coverage status
FOR ONCOLOGISTS
An expertise resource
PhD-level scientific staff interprets test results and payer-access experts deal with coverage and insurance documentation, at any point in treatment, for any patient.
NCPO Scientific Team
To: Dr. A. Chen
The expert-reviewed evidence report for your case is attached: candidate FDA-approved cancer drugs, ranked by the result of the living-cell test. The medical-necessity draft is ready for your signature.
N26709 evidence report.pdf
N26709 medical_necessity.pdf
FOR HOSPITALS
A cost-savings resource
NCPO enables personalized oncology without cost to hospitals, offering lab relationships, scientific staff, and payer processes. Hospitals use their own pathology and oncologists.
Personalized Oncology
Resources
Requirements
Support
New offices or laboratories
None
New equipment
None
New scientific staff
None
Cost to the hospital
$0
NCPO's work is free to the hospital and to the oncologist.
The tests and the drugs are not. That is the access gap NCPO exists to fill.
NCPO is guided by leaders in oncology, genomics, diagnostics, and AI.
The National Center for Personalized Oncology is a national resource for all US medical oncologists. It was founded in 2026 by Cancer Commons, a 501(c)(3) public charity that has provided personalized guidance to more than 10,000 cancer patients and works with more than 100 oncologists.
If your patient has run out of NCCN-guideline options, NCPO helps you with the scientific evidence to identify effective off-guideline drugs, and the payer access to get them covered. You select and prescribe. Your patient stays with you.
NCPO works to widen what your oncologist can offer, by identifying FDA-approved treatments beyond the standard guidelines and helping secure access to them. While NCPO works with your oncologist, Cancer Commons provides you with free guidance.
If you care about extending access to cancer treatments, NCPO offers a capital-efficient way to do it. Philanthropy funds a lean, AI-assisted national resource that equips oncologists nationwide at no cost to them and their practice.
